EN
DE
Home
About us
Biofronteras Expertise
Management and supervisory board
Product Pipeline
Clinical trials
Products
Product Portfolio
Investors
Key stock information
Financial reports
Financial announcements
Shareholder structure
Corporate calendar
Corporate governance
Annual general meeting
SEC reporting
FAQs Delisting BFRA
Takeover Offer of Deutsche Balaton AG
Presentations & contact
Career
Careers
Contact
Biofrontera
Investors
Financial announcements
Material News
Material News
No news available.
Material News archive
2022
2022
11/21/2022 21:50
PTA-Adhoc: Biofrontera AG: Biofrontera is going to submit proposal for resolution on capital increase at an extraordinary shareholders' meeting
11/11/2022 18:10
PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022
09/22/2022 13:15
PTA-Adhoc: Biofrontera AG: Higher Regional Court of Cologne grants release of the capital increase
08/23/2022 10:55
PTA-Adhoc: Biofrontera AG: Exclusion of the Maruho Deutschland GmbH from today's Annual General Meeting
08/19/2022 21:15
PTA-Adhoc: Biofrontera AG: Appointment of Mrs Pilar de la Huerta Martinez as new Chief Financial Officer
08/13/2022 21:40
PTA-Adhoc: Biofrontera AG: Dismissal of Chief Financial Officer Ludwig Lutter for cause
08/02/2022 16:10
PTA-Adhoc: Biofrontera AG: Major shareholders submit competing election proposals for elections to the Supervisory Board
06/09/2022 18:10
PTA-Adhoc: Biofrontera AG: Supervisory Board of Biofrontera AG appoints Paul Böckmann to the Management Board
06/02/2022 19:55
PTA-Adhoc: Biofrontera AG: Biofrontera AG will terminate its U.S. ADS program
04/29/2022 23:40
PTA-Adhoc: Biofrontera AG: Biofrontera AG specifies its guidance for the financial year 2022
04/04/2022 18:00
PTA-Adhoc: Biofrontera AG: Biofrontera announces first preliminary unaudited results for fiscal year 2021 and financial guidance for 2022
02/24/2022 18:30
PTA-Adhoc: Biofrontera AG: Biofrontera is going to submit proposals for resolutions on capital measures at an extraordinary shareholders' meeting
02/22/2022 15:20
PTA-Adhoc: Biofrontera AG: Changes in the supervisory board
02/14/2022 20:05
PTA-Adhoc: Biofrontera AG: Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
01/13/2022 14:45
PTA-Adhoc: Biofrontera AG: Biofrontera announces preliminary revenue figures for the full year 2021
2021
2021
12/29/2021 10:20
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces reduction of shareholding in Biofrontera Inc. below 50%
12/02/2021 08:50
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces timing of the departure of the CEO
12/02/2021 01:05
PTA-Adhoc: Biofrontera AG: Biofrontera Inc. announces closing of USD15 million private placement
11/29/2021 16:20
PTA-Adhoc: Biofrontera AG: Biofrontera Inc. announces USD15 million private placement
11/29/2021 15:15
PTA-Adhoc: Biofrontera AG: Biofrontera reaches out-of-court settlement with DUSA Pharmaceuticals, Inc.
11/19/2021 14:45
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces mediation results
11/10/2021 14:10
PTA-Adhoc: Biofrontera AG: CEO seeks early retirement from the Management Board
11/03/2021 14:45
PTA-Adhoc: Biofrontera AG: Early repayment of EIB loan
11/02/2021 19:45
PTA-Adhoc: Biofrontera AG: Biofrontera Inc. closes IPO
10/29/2021 03:40
PTA-Adhoc: Biofrontera AG: Initial public offering price of Biofrontera Inc. IPO
10/27/2021 18:35
PTA-Adhoc: Biofrontera AG: Biofrontera AG approves modification of the US-IPO of Biofrontera Inc.
10/22/2021 15:55
PTA-Adhoc: Biofrontera AG: Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
10/01/2021 15:21
PTA-Adhoc: Biofrontera AG: Biofrontera AG approves IPO of Biofrontera Inc. in the USA
07/06/2021 23:59
PTA-Adhoc: Biofrontera AG: Biofrontera Inc. seeks IPO in the USA
02/24/2021 00:50
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces results of the capital increase resolved on May 28, 2020 - Gross proceeds of EUR 24.7 million
02/18/2021 15:15
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces subscription price of new shares from capital increase resolved on May 28, 2020
02/04/2021 16:15
PTA-Adhoc: Biofrontera AG: Details of the capital increase resolved on May 28, 2020 - Subscription period begins February 08, 2021
01/08/2021 15:35
PTA-Adhoc: Biofrontera AG: Biofrontera announces preliminary revenue figures for the full year 2020
01/07/2021 17:45
PTA-Adhoc: Biofrontera AG: Cologne Higher Regional Court grants approval of capital increase
Ad Hoc News PDF archive
2020 (since April 2020)
2020 (since April 2020)
11/12/2020 10:27
PTA-Adhoc: Biofrontera AG: Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds
10/09/2020 16:32
PTA-Adhoc: Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the third quarter of 2020
09/11/2020 13:30
PTA-Adhoc: Biofrontera AG: Biofrontera AG plans mediation to resolve (legal) disputes
08/13/2020 22:50
PTA-Adhoc: Biofrontera AG: Result of the subscription of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
08/10/2020 16:00
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021
07/27/2020 19:15
PTA-Adhoc: Biofrontera AG: Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
07/14/2020 12:08
PTA-Adhoc: Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the first six months of 2020
2020 (until April 2020)
2020 (until April 2020)
20200303_Ad_hoc_binding_term-sheet_Maruho_EN_final.pdf
20200323_Ad_hoc_withdrawal_subscribtion_CB_EN_final.pdf
20200313_Ad_hoc_non-binding_term_sheet_Poland_EN_final.pdf
20200312_Ad_hoc_extension_subscription_period_CB_EN_final.pdf
20200226_Ad_hoc_convertible_bond_EN_final.pdf
20200110_Ad_hoc_Prelim_results_Q4_EN_final.pdf
20200420_Ad_hoc_Maruho_license_agreement_EN_final.pdf
20200416_Ad_hoc_resolution_for_ordinary_capital_increase_AGM_EN_final.pdf
Publication pursuant to Section 111c AktG 11.03.2020
2019
2019
2019.11.19_Adhoc_Q3EarningsRelease_EN_final.pdf
(116 KB)
2019.10.10_Adhoc_prelimQ3_EN.pdf
(3 MB)
2019.03.25_Adhoc_CLS_EN_final.pdf
(115 KB)
2019.03.20_Adhoc_study results_EN.pdf
(78 KB)
2019.03.19_Adhoc_MaruhoBrandedGenerics_EN.PDF
(46 KB)
2019.01.22_Adhoc_PrelimQ4_EN_final.pdf
(116 KB)
2018
2018
20181010_Adhoc Meldung_Prelim Q3_EN_final.pdf
(175 KB)
20180412 ad hoc_Q1results_EN.pdf
(43 KB)
20180305_ad hoc_Daylight approval_EN.pdf
(45 KB)
ad_hoc_20180213_EN_KE_results_final.pdf
(43 KB)
ad_hoc_20180209_EN_KE_price.pdf
(58 KB)
ad_hoc_20180131_EN_KE_price_range.pdf
(44 KB)
ad_hoc_20180129_EN_daylight.pdf
(43 KB)
20180129 Ad-hoc KE_EN.pdf
(37 KB)
ad_hoc_20180123_EN_final.pdf
(47 KB)
ad_hoc_nasdaq_EN_final.pdf
(43 KB)
2017
2017
01/24/2017 Ad-hoc: Bond Issue: 49.990 subordinate convertible debenture fully placed
(79 KB)
01/30/2017 Ad-hoc: European Commission extends Ameluz® approval to basal cell carcinoma
(33 KB)
02/06/2017 Ad-hoc: Biofrontera Reports Positive Phase III Results for Ameluz® in Combination with Daylight-PDT
(82 KB)
05/19/2017 Ad-hoc: Biofrontera enters into finance contract with European Investmentbank
(154 KB)
07/28/2017 Ad-hoc: Biofrontera AG: Warrant bond 2009/2017 will be repaid early
(33 KB)
11/14/2017 Ad-hoc: Biofrontera adjusts revenues and earnings forecast for the financial year 2017
(64 KB)
2016
2016
01/04/2016 Ad-hoc: RNS release: Total Voting Rights
(75 KB)
01/20/2016 Ad-hoc: RNS release: Notice of Cancellation from Trading on AIM
(169 KB)
01/28/2016 Ad-hoc: Biofrontera‘s Ameluz® achieves excellent results in clinical study for basal cell carcinoma
(218 KB)
02/16/2016 Ad-hoc: Biofrontera AG resolves on capital increase
(79 KB)
03/24/2016 Ad-hoc: Biofrontera AG anticipates capital increase
(78 KB)
03/29/2016 Ad-hoc: Biofrontera AG resolves on capital increase
(93 KB)
04/18/2016 Ad-hoc: Capital increase several times oversubscribed
(36 KB)
05/11/2016 Ad-hoc: FDA grants approval for Ameluz® in the USA
(79 KB)
07/13/2016 Ad-hoc: Biofrontera AG and Maruho Initiate Joint Project to Explore Development Opportunities
(92 KB)
10/31/2016 Ad-hoc: Biofrontera AG resolves on capital increase and issue of convertible bonds
(79 KB)
11/17/2016 Ad-hoc: Capital Increase: 5,012,950 New Shares fully placed
(33 KB)
11/24/2016 Ad-hoc: Bond Issue: 49,990 subordinate convertible debentures fully placed
(33 KB)
12/23/2016 Ad-hoc: Biofrontera AG resolves on issue of convertible bonds
(81 KB)
2015
2015
04/09/2015 Ad-hoc: RNS release: Final Results 2014
(479 KB)
04/23/2015 Ad-hoc: Biofrontera AG – Biofrontera AG resolves on capital increase
(121 KB)
04/23/2015 Ad-hoc: RNS release: Open Offer and Private Placement
(77 KB)
04/27/2015 Ad-hoc: RNS Release: Further re: Subscription Offer and Private Placement
(275 KB)
04/27/2015 Ad-hoc: Subscription offer from the capital increase resolved upon on 04/23/2015 from authorized capital
(178 KB)
05/27/2015 Ad-hoc: Biofrontera AG – 1,377,272 shares placed in capital increase
(78 KB)
07/16/2015 Ad-hoc: RNS release: Notice of Annual General Meeting
(94 KB)
08/13/2015 Ad-hoc: RNS release: Half Year Results - Good progress made in first half of 2015
(274 KB)
09/12/2015 Ad-hoc: FDA accepts filing of Ameluz® and BF-RhodoLED® application
(119 KB)
10/27/2015 Ad-hoc: Biofrontera AG – Biofrontera AG resolves on capital increase
(37 KB)
10/27/2015 Ad-hoc: RNS release: Open Offer and Private Placement
(22 KB)
10/28/2015 Ad-hoc: RNS release: Further re - Open Offer and Private Placement
(446 KB)
11/05/2015 Ad-hoc: Biofrontera AG – subscription price for New Shares from ongoing capital increase determined
(121 KB)
11/23/2015 Ad-hoc: Biofrontera AG – 1.9 mio shares placed in capital increase
(139 KB)
12/10/2015 RNS release: Issue of equity and total voting rights
(76 KB)